State Street Corp Gain Therapeutics, Inc. Transaction History
State Street Corp
- $2.41 Trillion
- Q3 2024
A detailed history of State Street Corp transactions in Gain Therapeutics, Inc. stock. As of the latest transaction made, State Street Corp holds 34,437 shares of GANX stock, worth $70,251. This represents 0.0% of its overall portfolio holdings.
Number of Shares
34,437
Previous 34,437
-0.0%
Holding current value
$70,251
Previous $44,000
38.64%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding GANX
# of Institutions
23Shares Held
2.39MCall Options Held
10KPut Options Held
0-
David Einhorn Greenlight Capital Inc | New York, Ny588KShares$1.2 Million0.1% of portfolio
-
Dme Capital Management, LP New York, NY566KShares$1.15 Million0.04% of portfolio
-
Joel Greenblatt Gotham Asset Management, LLC | New York, Ny335KShares$682,5670.01% of portfolio
-
Geode Capital Management, LLC Boston, MA272KShares$554,8220.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA145KShares$296,2420.0% of portfolio
About Gain Therapeutics, Inc.
- Ticker GANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,883,400
- Market Cap $24.2M
- Description
- Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietar...